Get the Stockscreener App
284.73
0.16%
-0.46
United Therapeutics Corp stock is traded at $284.73, with a volume of 302.95K.
It is down -0.16% in the last 24 hours and down -11.83% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$285.19
Open:
$284.67
24h Volume:
302.95K
Relative Volume:
0.65
Market Cap:
$12.77B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
12.50
EPS:
22.77
Net Cash Flow:
$898.10M
1W Performance:
+2.09%
1M Performance:
-11.83%
6M Performance:
-23.63%
1Y Performance:
+21.00%
1-Day Range:
$279.95
$287.45
1-Week Range:
$276.39
$288.54
52-Week Range:
$233.28
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics director Raymond Dwek sells $855,480 in stock - Investing.com Australia
United Therapeutics Schedules Key Q1 2025 Financial Results: What Pharma Investors Should Watch - Stock Titan
United Therapeutics director Raymond Dwek sells $855,480 in stock By Investing.com - Investing.com Canada
Here's Why United Therapeutics (UTHR) is a Strong Value Stock - Yahoo Finance
United Therapeutics director Raymond Dwek sells shares for $1.14 million - Investing.com Australia
United Therapeutics director Raymond Dwek sells shares for $1.14 million By Investing.com - Investing.com India
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics EVP sells $3.37 million in stock By Investing.com - Investing.com Australia
United Therapeutics EVP sells $3.37 million in stock - Investing.com
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4 - Yahoo Finance
Game-Changing Transplant Data: United Therapeutics Unveils 10 Major Studies at ISHLT 2025 - Stock Titan
Fortune Names This Innovative Biotech Among Best Companies to Work For in 2025 - Stock Titan
Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLC - MarketBeat
Korea Investment CORP Acquires 2,300 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Prudential Financial Inc. Buys 12,104 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics: Don't Fear The Patent Expiration Too Much (NASDAQ:UTHR) - Seeking Alpha
Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? - Insider Monkey
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
3 Reasons Investors Watch United Therapeutics (UTHR) - The Globe and Mail
United Therapeutics director sells $796,990 in stock By Investing.com - Investing.com Australia
United Therapeutics director sells $796,990 in stock - Investing.com
First Week of November 21st Options Trading For United Therapeutics (UTHR) - Nasdaq
United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada
United Therapeutics director sells $1.55 million in stock - Investing.com India
Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com
United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks
Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
United Therapeutics at Leerink’s Global Healthcare Conference: Strategic Growth and Innovation - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Apr 17 '25 |
Sale |
283.78 |
11,000 |
3,121,543 |
36,781 |
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):